Finnish Pekka Simula is a Partner at Innovestor Life Science and has over 20 years of experience in the health and life sciences industry, including as founder and CEO of Oncos Therapeutics, and CEO of Herantis Pharma, which went public in 2014. The Innovestor Life Science Fund is €90 million and invests in companies from pre-seed to Series A. They prefer to collaborate with other specialist investors, he explains.
"We want to invest in teams who know what they know, together with investors who know what they know. We invest in both therapeutics and digital health, and the solutions the company offers should directly impact the diagnosis, treatment, or management of patients or the discovery and development of new diagnostic or treatment options."
Simula emphasizes the importance of the business model when evaluating companies.
"Some companies in the discovery stage have a business model focused on selling services to the pharmaceutical industry, which can be a profitable business but may not align with the venture capital firm's goal of seeking high returns on investment.”
Having the same goals and being compatible are important in a partnership. He therefore has some practical advice for companies seeking an investor:
1. Define your business model.
2. Know your expertise gaps.
3. Determine if you want to navigate solo or together.